A Phase I Study Evaluating Combined Zevalin (Ibritumomab Tiuxetan) and Valcade (Bortezomib) in Relapsed/Refractory Low-Grade or Follicular B-Cell and Mantle Cell Lymphoma

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed low-grade, follicular B-cell, or mantle cell non-Hodgkin's
lymphoma

- Bone marrow biopsy required for pretreatment evaluation

- Unilateral bone marrow biopsy allowed

- Core biopsies allowed if they contain adequate tissue for primary diagnosis
and immunophenotyping

- Relapsed or refractory disease as defined by disease progression after initial
complete response (CR) or failure to achieve CR

- No bone marrow involvement ≥ 25% within the past 30 days

- No pleural effusion or significant ascites

- No active CNS involvement

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy ≥ 3 months

- Platelet count ≥ 100,000/mm^3

- Absolute neutrophil count ≥ 1,500/mm^3

- AST ≤ 2.5 times upper limit of normal (ULN)

- Total bilirubin ≤ 2.5 times ULN

- Creatinine clearance ≥ 50 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Hepatitis B surface antigen negative

- No current infection with hepatitis B virus

- No HIV positivity

- No neuropathy or neuropathic pain ≥ grade 2

- No history of allergic reaction to boron or mannitol

- No active serious infection or medical or psychiatric illness that would preclude
study therapy

- No other malignancy within the past 5 years except for the following:

- Basal cell or squamous cell carcinoma of the skin that has been completely
resected

- In situ malignancy that has been completely resected

- T1-T2a, N0, M0 prostate cancer treated with a prostatectomy or radiotherapy
within the past 2 years with an undetectable PSA level

- No other condition, including any of the following:

- Myocardial infarction within the past 6 months

- New York Heart Association class III-IV heart failure

- Uncontrolled angina

- Severe uncontrolled ventricular arrhythmias

- Electrocardiographic evidence of acute ischemia or active conduction system
abnormalities

PRIOR CONCURRENT THERAPY:

- Recovered from all prior therapy

- More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C),
radiotherapy, or surgical resection of malignancy

- No limitations on the number of prior therapies

- More than 4 weeks since prior major surgery

- More than 14 days since prior filgrastim (G-CSF) or sargramostim (GM-CSF)

- More than 14 days since prior and no other concurrent investigational agents

- Concurrent participation in a nontreatment study allowed

- No prior radioimmunotherapy